Stoke Therapeutics (STOK) Revenue (2022 - 2026)

Stoke Therapeutics has reported Revenue for 5 years, with the latest figure at $6.2 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue fell 96.07% year-over-year to $6.2 million; the trailing twelve-month figure through Mar 2026 stood at $32.1 million (down 83.2% YoY), and the FY2025 full-year result was $184.4 million, up 404.5% from the prior year.
• Revenue for Q1 2026 stood at $6.2 million, up from $1.4 million in the prior quarter.
• The five-year high for Revenue was $158.6 million in Q1 2025, with the low at $1.4 million in Q4 2025.
• Average Revenue over 5 years is $14.9 million, with a median of $4.2 million recorded in 2024.
• Year-over-year, Revenue soared 3661.12% in 2025 and slumped 96.07% in 2026.
• Tracing STOK's Revenue over 5 years: stood at $3.3 million in 2022, then decreased by 14.26% to $2.8 million in 2023, then jumped by 707.07% to $22.6 million in 2024, then plunged by 93.8% to $1.4 million in 2025, then jumped by 344.29% to $6.2 million in 2026.
• The last three Revenue figures came in at $6.2 million (Q1 2026), $1.4 million (Q4 2025), and $10.6 million (Q3 2025), per Business Quant data.

Peer Comparison